about
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected childrenSuccess rates for consent and collection of prenatal biological specimens in an epidemiologic survey of child healthUrinary concentrations of environmental phenols in pregnant women in a pilot study of the National Children's StudyPrenatal mercury concentration is associated with changes in DNA methylation at TCEANC2 in newbornsPredictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapyTotal body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection.Planned variation in preanalytical conditions to evaluate biospecimen stability in the National Children's Study (NCS).Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIVAssociations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapySafety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.Exploring the associations between microRNA expression profiles and environmental pollutants in human placenta from the National Children's Study (NCS)Three postpartum antiretroviral regimens to prevent intrapartum HIV infectionConsenting postpartum women for use of routinely collected biospecimens and/or future biospecimen collection.Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees CIodine status in pregnant women in the National Children's Study and in U.S. women (15-44 years), National Health and Nutrition Examination Survey 2005-2010Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.Randomized controlled trial of feeding a concentrated formula to infants born to women infected by human immunodeficiency virusSelected persistent organic pollutants in human placental tissue from the United States.Nevirapine concentrations in newborns receiving an extended prophylactic regimen.Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection.Insulin-like growth factor-1 and lean body mass in HIV-infected children.Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV.Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia.Endocrine abnormalities and impaired growth in human immunodeficiency virus-infected children.Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group.Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection. The Women and Infants Transmission Study Group.Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis.Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings.The use of human tissues in research: what do we owe the research subjects?
P50
Q24679084-4BA2FD7F-B5FE-484A-87E6-4EE12D5E1F47Q28384516-E3DE7ACA-825C-4C6E-AFC6-70A3725804C5Q28385431-1F517A43-D8CC-4C83-8390-5C5F79FE02D0Q28389914-61FDF9D5-E233-469B-865D-91FECB2B7255Q28741211-3A5DF948-BB1F-4160-ACD6-5C587B3BD1D7Q33532361-8226369D-8A62-4697-96D0-813BF2BF4E7BQ33788608-40C017D6-2D16-4678-97DC-3F12DDA58E10Q33910314-AE5F1D39-5E13-47B2-9B1B-1204245FCFD8Q33996797-75101DD8-88BE-4F4A-864F-45FABB3401CAQ34036150-37FC9174-5392-49FA-A53F-EDEBA01C1A5EQ34348304-8931FE4B-DD3B-4B1D-90EF-2CFF81FC71B5Q35127616-AA66BE79-F259-4E2C-941A-890611BFDDD8Q35171059-B91323DE-E645-4978-B5EA-621E2E89DBD7Q36214069-ED52C4FC-98D9-4258-A6F9-AFCC546053FBQ36662110-C5183808-3A86-48FE-8CA8-94511BFD0A4FQ36698388-E8A01559-1F7D-4131-AD5E-0CCF1B5B8127Q36814047-C5E41654-7A52-4336-AD47-BD08A6878E8AQ36898309-292C90E8-25FF-4AFF-928A-8B31A626D3B3Q37118661-6CDD8386-78E4-439E-BEC4-D6B9573DB1ECQ37187093-64E94E75-F3E0-4A5C-B117-249A678711E7Q37371323-C3BE80AA-C339-429E-BD5E-9FB69EE45268Q37435125-C43DF934-8D3C-4013-8162-6B5E73D684DFQ37602651-30203ECC-CAC5-4680-8D96-7D192F5B3E13Q37665959-548C2646-D228-49C1-8FB2-5900DB936D7DQ43708324-CAE8ACE0-CCD5-419B-8801-B7035C2B2691Q43907205-77869DA7-DD82-447F-9A4E-F0719581A338Q44681462-CB5A00ED-3AE9-4F38-9D66-60A92E37A0F9Q44690950-8992FA9C-A4FB-472E-B9E9-F0A2CB6999A8Q44835871-47F55828-B010-47DD-89C1-B115C0998F72Q44960395-043078DC-E842-4A40-9DD5-5271801B1EE0Q45396615-4DF70780-E552-4AD4-A581-A2ED7DDA0478Q45408717-6BAB2164-94E3-40F4-B960-E2904DCBF366Q45485328-850510DE-B4B3-405A-8736-F67A2B676287Q45722744-7EEEA847-C97B-407C-9FB5-97998AF9DDB6Q45748047-598B409C-F8C9-4E68-ABF5-73E374016A3FQ45772271-7E75FDA6-60E2-4153-8EE7-E460331D1941Q45782912-5FC5B06F-CC3D-465C-8CDF-C8F278DF9AA1Q46346962-16489B7A-3B92-47BD-872A-E98108A190EEQ46347977-55F07814-67AC-4C80-A67B-3E01D99BEBB8Q48714690-7586A1FA-DFBE-4E67-9665-DC97C0572F18
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jack Moye
@ast
Jack Moye
@en
Jack Moye
@es
Jack Moye
@nl
type
label
Jack Moye
@ast
Jack Moye
@en
Jack Moye
@es
Jack Moye
@nl
prefLabel
Jack Moye
@ast
Jack Moye
@en
Jack Moye
@es
Jack Moye
@nl
P106
P1153
7006639318
P21
P31
P496
0000-0001-9976-8586